| 1.16 -0.12 (-9.38%) | 04-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.61 |
1-year : | 1.78 |
| Resists | First : | 1.38 |
Second : | 1.52 |
| Pivot price | 1.33 |
|||
| Supports | First : | 1.13 |
Second : | 0.94 |
| MAs | MA(5) : | 1.25 |
MA(20) : | 1.34 |
| MA(100) : | 1.76 |
MA(250) : | 1.41 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 28 |
D(3) : | 27.7  |
| RSI | RSI(14): 37.3 |
|||
| 52-week | High : | 3.12 | Low : | 0.62 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ EKSO ] has closed above bottom band by 0.7%. Bollinger Bands are 55.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 20 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.31 - 1.32 | 1.32 - 1.33 |
| Low: | 1.12 - 1.13 | 1.13 - 1.14 |
| Close: | 1.15 - 1.16 | 1.16 - 1.17 |
Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. It also provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; and EksoUE is a wearable upper extremity assistive device that helps to reduce the effect of gravity on the wearer's shoulders and arms. Ekso Bionics Holdings, Inc. has a license agreement with Lockheed Martin Corporation. The company was incorporated in 2005 and is headquartered in Richmond, California.
Mon, 22 Apr 2024
Ekso Bionics to Report First Quarter 2024 Financial Results on April 29, 2024 - Yahoo Canada Finance
Fri, 12 Apr 2024
Ekso Bionics secures Medicare reimbursement for exoskeleton By Investing.com - Investing.com Nigeria
Fri, 12 Apr 2024
Ekso Bionics Receives Final Payment Determination for Medicare Reimbursement from the Centers for Medicare ... - GlobeNewswire
Wed, 06 Mar 2024
Marin County’s Ekso Bionics posts record revenue for 2023, Q4 - North Bay Business Journal
Mon, 04 Mar 2024
Ekso Bionics Reports Record Annual Revenue of $18.3 Million - GlobeNewswire
Mon, 04 Mar 2024
Ekso Bionics Holdings, Inc. (EKSO) Q4 2023 Earnings Call Transcript - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 18 (M) |
| Shares Float | 16 (M) |
| Held by Insiders | 13.5 (%) |
| Held by Institutions | 7.6 (%) |
| Shares Short | 134 (K) |
| Shares Short P.Month | 145 (K) |
| EPS | -1.11 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.85 |
| Profit Margin | -83.2 % |
| Operating Margin | -71.2 % |
| Return on Assets (ttm) | -27.1 % |
| Return on Equity (ttm) | -79.9 % |
| Qtrly Rev. Growth | 36.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.02 |
| EBITDA (p.s.) | -0.75 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -1.06 |
| PEG Ratio | 0 |
| Price to Book value | 1.36 |
| Price to Sales | 1.13 |
| Price to Cash Flow | -1.73 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|